CTSO

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · derivative · entry 3

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,625

Underlying: Common Stock · 32,625 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F6 · derivative.exercise_price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F6 · price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F7 · derivative.expiration_date: The Series A Right Warrants expire 45 calendar days following the Closing Date.

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · derivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,625 shares

Expires 2025-01-10

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 433,988

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F1 · price: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F4 · balance_after: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F5 · balance_after: (continued from footnote 4) (d) 83,988 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-25-005353 · tm254168-4_4seq1.xml · derivative · entry 4

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,832

Underlying: Common Stock · 90,832 shares

Expires 2025-04-10

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F8 · derivative.exercise_price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F8 · price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F9 · derivative.expiration_date: The Series B Right Warrants expire 90 calendar days following the Closing Date.

SEC source: 0001104659-25-005353 · tm254168-4_4seq1.xml · derivative · entry 3

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,832

Underlying: Common Stock · 90,832 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F6 · derivative.exercise_price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F6 · price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F7 · derivative.expiration_date: The Series A Right Warrants expire 45 calendar days following the Closing Date.

SEC source: 0001104659-25-005353 · tm254168-4_4seq1.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,832 shares

Expires 2025-01-10

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the "Closing Date").

SEC source: 0001104659-25-005353 · tm254168-4_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,243,195

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F1 · price: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 90,832 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $90,832. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 87,000 RSUs granted on July 7, 2023 and of which 29,000 RSUs remain unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 902,195 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-128667 · tm2431157-1_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,363

F1 · kind: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8902 to $1.09. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F1 · price: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8902 to $1.09. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F2 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F4 · balance_after: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F5 · balance_after: (continued from footnote 4) (d) 51,363 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-24-128223 · tm2431024-1_4seq1.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,363

F2 · kind: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.88 to $0.90. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F2 · price: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.88 to $0.90. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F3 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F4 · balance_after: (continued from footnote 3) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F5 · balance_after: (continued from footnote 4) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F6 · balance_after: (continued from footnote 5) (d) 31,363 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-24-128223 · tm2431024-1_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 361,363

F1 · kind: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8289 to $0.92. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F1 · price: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8289 to $0.92. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

SEC source: 0001104659-24-107141 · tm2425809-1_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-10-04

F2 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F2 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-107141 · tm2425809-1_4seq1.xml · derivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-10-04

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-107142 · tm2425809-2_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-10-04

F2 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F2 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-107142 · tm2425809-2_4seq1.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-10-04

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · derivative · entry 5

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2034-08-14

F5 · derivative.exercise_date: The shares underlying these stock options will vest only upon the achievement of certain milestones pursuant to the terms of the Employment Agreement, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · derivative · entry 4

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2034-08-14

F4 · derivative.exercise_date: The shares underlying these stock options vest in accordance with the following schedule: (i) 41,000 upon the six-month anniversary of the date of grant, and (ii) 13,000 on the one-year, two-year and three-year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

F3 · shares: These shares represent RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the reporting person's employment agreement, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

F2 · shares: These shares represent RSUs which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

F1 · shares: These shares represent restricted stock units ("RSUs") received as a signing bonus that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon the earlier of (i) a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the reporting person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043796 · tm2411149-6_4seq1.xml · derivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · Not disclosed shares

Expires 2034-04-02

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043795 · tm2411149-3_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,000

Underlying: Common Stock · 86,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043795 · tm2411149-3_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,433

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of common stock, par value $0.001 per share (the "Common Stock") upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and

F5 · balance_after: (continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-043794 · tm2411149-8_4seq1.xml · derivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-04-02

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043793 · tm2411149-2_4seq1.xml · derivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043793 · tm2411149-2_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 532,941

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock"), upon vesting: 20,000 RSUs granted on September 18, 2023;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs, which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and

F5 · balance_after: (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-043792 · tm2411149-5_4seq1.xml · derivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-04-02

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043790 · tm2411149-4_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 101,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043790 · tm2411149-4_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 665,134

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 23,000 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 281,134 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-043789 · tm2411149-7_4seq1.xml · derivative · entry 1

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-04-02

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043788 · tm2411149-1_4seq1.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,000

Underlying: Common Stock · 124,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043788 · tm2411149-1_4seq1.xml · nonDerivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,164,704

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 87,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first year anniversary of the date of grant, and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 26,334 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 739,370 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-042776 · tm2410664-4_4seq1.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,088

Underlying: Common Stock · 47,088 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-042775 · tm2410664-3_4seq1.xml · derivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,923

Underlying: Common Stock · 129,998 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-042772 · tm2410664-1_4seq1.xml · derivative · entry 1

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,998

Underlying: Common Stock · 129,998 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-042774 · tm2410664-2_4seq1.xml · derivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,038

Underlying: Common Stock · 49,038 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-126432 · tm2332958-5_4seq1.xml · derivative · entry 3

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,894

Underlying: Common Stock · 7,894 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126432 · tm2332958-5_4seq1.xml · nonDerivative · entry 1

Sobel Alan D. · CIK 0001639386 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,857

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person.

SEC source: 0001104659-23-126431 · tm2332958-4_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,894

Underlying: Common Stock · 7,894 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126431 · tm2332958-4_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 348,433

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes: (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of Common Stock upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and

F5 · balance_after: (continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-126430 · tm2332958-6_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,578

Underlying: Common Stock · 6,578 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126430 · tm2332958-6_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 584,134

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 73,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 23,000 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 281,134 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-126429 · tm2332958-3_4seq1.xml · derivative · entry 2

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,157

Underlying: Common Stock · 13,157 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126429 · tm2332958-3_4seq1.xml · nonDerivative · entry 1

BATOR MICHAEL G. · CIK 0001647591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,394

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 56,094 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-126428 · tm2332958-7_4seq1.xml · derivative · entry 2

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,631

Underlying: Common Stock · 2,631 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126428 · tm2332958-7_4seq1.xml · nonDerivative · entry 1

Jones Edward Raymond · CIK 0001396246 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,834

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes: (i) the following Restricted Stock Units ("RSUs") that will be settled into Common Stock vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-126424 · tm2332958-8_4seq1.xml · derivative · entry 2

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,631

Underlying: Common Stock · 2,631 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126424 · tm2332958-8_4seq1.xml · nonDerivative · entry 1

Kim Jiny · CIK 0001920967 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,819

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-126427 · tm2332958-2_4seq1.xml · derivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,157

Underlying: Common Stock · 13,157 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

SEC source: 0001104659-23-126427 · tm2332958-2_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,941

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

F2 · balance_after: Includes: (i) the following restricted stock units ("RSUs") (which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 20,000 RSUs granted on September 18, 2023;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and

F5 · balance_after: (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-126421 · tm2332958-1_4seq1.xml · derivative · entry 2

Chan Phillip P. · CIK 0001442786 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,315

Underlying: Common Stock · 26,315 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.